Michael White, professor of pharmacy practice at the University of Connecticut School of Pharmacy, is skeptical, to say the least: The marketing seems to suggest that you could get with these natural products, these natural ingredients, the same effect that you can get with GLP-1 agonists, which is simply not the case
When additional therapy is required, NICE recommends considering a GLP-1 receptor agonist (such as Rybelsus) if the patient has a BMI of 35 kg/m or higher (or 32.5 kg/m or higher for people of South Asian or related ethnicity) and specific psychological or medical problems associated with obesity, or if BMI is lower but insulin therapy would have significant occupational implications or weight loss would benefit other obesity-related comorbidities
Significant appetite suppression already present at current dose, since the primary mechanism is already engaged
The counterargument is that SGLT-2i probably has a stronger case in relation to cardiovascular protection, particularly reduction in heart failure hospitalization, but these agents can be problematic in those with urinary tract pathologies or significant renal impairment
RodionovRNDayoubHLynchCMWilsonKMStevensJWMurryDJet alOverexpression of dimethylarginine dimethylaminohydrolase protects against cerebral vascular effects of hyperhomocysteinemia
It works by enhancing insulin secretion in response to meals, suppressing glucagon release, slowing gastric emptying, and reducing appetite